R&D Expenses: Research and development (R&D) expenses were $13.4 million for the quarter ended December 31, 2025, and $59.1 million for the year ended December 31, 2025. G&A Expenses: General and ...
Design Therapeutics, Inc. announced the initiation of a Phase 1 clinical trial for its gene-targeted treatment DT-216P2 in healthy volunteers, with patient dosing for Friedreich Ataxia (FA) set to ...
Design Plans to Proceed with an Improved DT-216 Formulation and Initiate a Multiple Dose Phase 1 Clinical Study in the Second Half of 2024 Conference Call and Webcast to be Held Today at 4:30pm ET ...
IND Application Submitted to Expand RESTORE-FA Trial to U.S. Sites; Notice Received from FDA Placing Clinical Hold on IND Application to Open U.S. Sites CARLSBAD, Calif., June 04, 2025 (GLOBE NEWSWIRE ...
RBC Capital Market downgraded Design Therapeutics Inc DSGN from Outperform to Sector Perform with a price target of $7, down from $23. The company reported initial results from the company's Phase 1 ...
CARLSBAD, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results